# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announc...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $30 ...
Oppenheimer analyst Jay Olson maintains Voyager Therapeutics (NASDAQ:VYGR) with a Outperform and maintains $18 price target.
Wedbush analyst Laura Chico maintains Voyager Therapeutics (NASDAQ:VYGR) with a Neutral and lowers the price target from $10...
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of ...
Translational potential of TRACER-derived AAV capsids demonstrated by data across multiple species (murine, porcine, multiple...